QXQingyu Xu

Qingyu Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qingyu Xu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Guowen Yin

    Interventional Radiology Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China

    4 shared publications
  • Bin Leng

    Department of Interventional Radiology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China

    3 shared publications
  • Chendong Wang

    Department of Interventional Radiology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China

    3 shared publications
  • Lingfeng Diao

    Department of Interventional Radiology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China

    3 shared publications
  • Ran You

    Department of Interventional Radiology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research The Affiliated Cancer Hospital of Nanjing Medical University Nanjing China

    3 shared publications
  • Zeyu Yu

    Interventional Radiology Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China

    3 shared publications

Latest Publications

  • Open Access

    Comparison of liver injury and inflammatory response following conventional and drug-eluting bead transcatheter chemoembolization in hepatocellular carcinoma

    by Ran You, Bin Leng, Chendong Wang, Zeyu Yu, Lingfeng Diao, Ya Lu, Qingyu Xu, Guowen Yin

    Objective This study aimed to compare the extent of liver injury and the inflammatory response in patients with hepatocellular carcinoma (HCC) following conventional transarterial chemoembolization (cTACE) and drug-eluting bead transarterial chemoembolization (DEB-TACE). Methods Clinical data from October 2018 to October 2019 were prospectively collected to establish a database. The baseline clinical and demographic characteristics of patients in the two groups were matched using propensity score matching (PSM). Serum levels of hepatic function indicators and inflammatory cytokines were evaluated before treatment and five days post-treatment. Results A total of 134 participants were included in the analysis. Following 1:1 PSM, 43 patients remained in each group, with no significant differences observed in baseline characteristics. The median absolute concentration of aspartate aminotransferase (AST) was significantly lower in the DEB-TACE group five days after treatment. Among 18 patients who experienced idiosyncratic drug-induced liver injury, the DEB-TACE group exhibited a significantly lower proportion of cases. The alanine aminotransferase/alkaline phosphatase (ALT/ALP) ratio was notably higher in the cTACE group, while cholestatic-type liver injuries were predominant in the DEB-TACE group. Levels of MCP-1, IL-6, and IL-1β were lower in the DEB-TACE group five days post-treatment. Additionally, MCP-1 levels were significantly correlated with ALT levels and the type of liver injury. Similarly, IL-6 levels showed significant correlations with ALT, AST, and the type of liver injury. Conclusions DEB-TACE was associated with reduced acute liver injury, characterized primarily by cholestatic injury, and a milder inflammatory response compared to cTACE. Post-treatment levels of MCP-1 and IL-6 levels were correlated with aminotransferase levels and the type of liver injury. Trial registration: Chinese Clinical Trial Registry, ChiCTR-1800017781. Register URL link: https://www.chictr.org.cn/showproj.html?proj=30041. Register date: 2018-8-14.


  • Open Access

    Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study

    by Zeyu Yu, Bin Leng, Ran You, Chendong Wang, Lingfeng Diao, Qingyu Xu, Guowen Yin

    Summary Purpose The combination therapy of lenvatinib and immunotherapy as first-line treatment remains controversial in unresectable hepatocellular carcinoma (uHCC). This research aimed to compare the efficacy and safety of lenvatinib monotherapy (L) and combination therapy of lenvatinib and immune checkpoint inhibitor (LI) in lenvatinib-insensitive patients with uHCC. Methods Two hundred fifty-five uHCC patients were enrolled in this study. Patients were classified into two groups: (1) Lenvatinib monotherapy (L); (2) Combination therapy (LI). Patients who remained stable disease (SD) but did not achieve complete response (CR) or partial response (PR) or progression disease (PD) for at least 3 months after receiving lenvatinib monotherapy were defined as lenvatinib-insensitive. Overall survival (OS) and progression-free survival (PFS), baseline characteristics, and safety were compared between groups. Results The LI group had longer OS (15.9 months vs. 11.9 months, P = 0.001) and PFS (12.6 months vs. 7.3 months, P < 0.001) than the L group. ECOG PS was an independent prognostic factor affecting OS and Up-to-seven was an independent prognostic factor affecting PFS. The frequency of grade ≥ 3 treatment-related adverse events (TRAEs) was not significantly different. Conclusions Our study demonstrated that the combination therapy (LI) had longer OS and PFS than the lenvatinib monotherapy (L) in lenvatinib-insensitive patients with uHCC.


  • Open Access

    A Transcriptomic Biomarker for Predicting the Response to TACE Correlates with the Tumor Microenvironment and Radiomics Features in Hepatocellular Carcinoma

    by Chendong Wang, Bin Leng, Ran You, Zeyu Yu, Ya Lu, Lingfeng Diao, Hao Jiang, Yuan Cheng, Guowen Yin, Qingyu Xu

    Purpose: The response to transarterial chemoembolization (TACE) varies among individuals with hepatocellular carcinoma (HCC). This study aimed to identify a biomarker for predicting TACE response in HCC patients and to investigate its correlations with the tumor microenvironment and pre-TACE radiomics features. Patients and Methods: GSE104580 data were obtained from the Gene Expression Omnibus (GEO) database. Differentially expressed gene analysis and machine learning algorithms were used to identify genes for constructing the TACE failure signature (TFS). TFS scores were then calculated for HCC patients in The Cancer Genome Atlas (TCGA) cohort. After obtaining images from The Cancer Imaging Archive (TCIA), tumor labeling and radiomics feature extraction, the Rad-score model was generated. Correlation analysis was performed between the TFS score and the Rad-score. CIBERSORT, ssGSEA and TME analysis were performed to explore differences in the immune landscape among distinct risk groups. The immunotherapy response was compared between different groups. Results: ADH1C, CXCL11, EMCN, SPARCL1 and LIN28B were selected and incorporated into the TFS, which demonstrated satisfactory performance in predicting TACE response. Patients in the high TFS score group had poorer overall survival (OS) than those in the low TFS score group. The Rad-score model was constructed using six radiomics features, and the Rad-score was significantly correlated with hub gene expression and the TFS score. The high-TFS group was also characterized by an immunosuppressive tumor microenvironment and exhibited unfavorable responses to immunotherapy with PD-1 and CTLA-4 checkpoint inhibitors. Conclusion: This study established a transcriptomic biomarker for predicting the efficacy of TACE that correlates with radiomics features on pretreatment imaging, tumor immune microenvironment characteristics, and the efficacy of immunotherapy and targeted therapy in HCC patients.


  • Open Access

    Immune-Targeted Therapy with or without Transarterial Chemoembolization (TACE) for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis (PVTT): A Multicenter Retrospective Study

    by Ran You, Yuan Cheng, Lingfeng Diao, Chendong Wang, Bin Leng, Zeyu Yu, Qingyu Xu, Guowen Yin

    Purpose: In the present study, we aimed to assess the effectiveness and safety of immune-targeted therapy (IT) with or without transarterial chemoembolization (TACE) for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). Patients and methods: This was a multicenter retrospective study that included 265 HCC patients with PVTT (IT + TACE: 82, IT: 183). Overall survival (OS) and progression-free survival (PFS), as well as tumor responses and adverse events, were evaluated. Results: Patients in the IT + TACE group experienced significantly longer overall survival (OS) and progression-free survival (PFS) periods, compared with those in the IT group (OS 19.0 vs. 13.0 months, p < 0.001; PFS 12.0 vs. 7.3 months, p < 0.001). Multivariable analysis confirmed IT + TACE as an independent predictor for improved OS and PFS. Subgroup analysis demonstrated the benefits of IT + TACE in patients with rich PVTT blood supply. Preoperative imaging and DSA offered predictive value. Conclusions: TACE combined with IT provides a safe and effective treatment option for advanced-HCC patients with PVTT, particularly those with abundant PVTT blood supply.


  • Open Access

    CPEB2 Suppresses Hepatocellular Carcinoma Epithelial–Mesenchymal Transition and Metastasis through Regulating the HIF-1α/miR-210-3p/CPEB2 Axis

    by Ran You, Yanjun Yang, Guowen Yin, Hao Jiang, Yousheng Lu, Liang Gui, Jun Bao, Qingyu Xu, Liang Feng

    Hepatocellular carcinoma (HCC) is a prevalent and high-mortality cancer worldwide, and its complexity necessitates novel strategies for drug selection and design. Current approaches primarily focus on reducing gene expression, while promoting gene overexpression remains a challenge. In this work, we studied the effect of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in HCC by constructing tissue microarrays (TAMs) from 90 HCC cases and corresponding para-cancerous tissues. Our analysis showed that CPEB2 expression was significantly reduced in HCC tissues, and its low expression was associated with a higher recurrence risk and poorer prognosis in patients with head and neck cancer. CPEB2 was found to regulate HCC epithelial–mesenchymal transition (EMT) and metastasis through the HIF-1α/miR-210-3p/CPEB2 feedback circuit. Using the RNA binding protein immunoprecipitation (RIP) assay, we demonstrated that miR-210 directly governs the expression of CPEB2. The inverse relationship between CPEB2 expression and miR-210-3p in HCC tissues suggested that this regulatory mechanism is directly linked to HCC metastasis, EMT, and clinical outcomes. Moreover, utilizing the SM2miR database, we identified drugs that can decrease miR-210-3p expression, consequently increasing CPEB2 expression and providing new insights for drug development. In conclusion, our findings illustrated a novel HIF-1α/miR-210-3p/CPEB2 regulatory signaling pathway in HCC and highlighted the potential of enhancing CPEB2 expression through targeting miR-210-3p as a novel predictive biomarker and therapeutic strategy in HCC, as it is modulated by the HIF-1α/miR-210-3p/CPEB2 feedback circuit.